CCL5, a proinflammatory chemokine, has been shown to attenuate angiotensin (Ang) II-induced expression of hypertensive mediators as well as Ang II-induced inhibition of anti-hypertensive mediator expression in vascular smooth muscle cells (VSMCs) of spontaneously hypertensive rats (SHR). In the present study, functional roles of CCL5 on hypertension were examined in developing hypertension state SHR (DHSHR). DHSHR at an age of 8 weeks were injected CCL5 (1.5 μg/kg) subcutaneously twice a day for 3 weeks (SHRi, n=5). Control groups consisted of normal age-matched saline-treated SHR (SHRc, n=5) and normotensive Wistar-Kyoto rats (WKY, n=5). Effect of CCL5 on blood pressure was measured before treatment, weekly during treatment, and 1 day after the final injection. After injecting for 3 weeks, effects of CCL5 on expression of hypertensive mediators were examined in thoracic aorta tissues and VSMCs. Blood pressure in SHRi was maintained without any elevation during the treatment period, whereas blood pressure in SHRc progressively increased with age. Expression of Ang II subtype I receptor was reduced in SHRi thoracic aorta tissues and VSMCs compared to those in SHRc. In addition, expression levels of hypertensive mediators were significantly reduced in SHRi thoracic aorta tissues and VSMCs compared to those in SHRc. In contrast, AMP-activated protein kinase (AMPK) activity and interleukin-10 (IL-10) expression were elevated in SHRi thoracic aorta tissues and VSMCs compared to levels in SHRc. These results suggest that reduction of hypertensive mediators and elevation of antihypertensive mediators by CCL5 treatment promotes maintenance of blood pressure in DHSHR.
INTRODUCTION
Increased activation of chemokines occurs in hypertensive arterial walls and mediates accumulation of inflammatory cells into the vasculature, which contributes to vascular inflammation in the pathogenesis of hypertension (1~4).
Indeed, inhibition of chemokine-induced inflammatory cell infiltration or chemokine receptors CXCR1 and CXCR2
has been shown to ameliorate hypertension in experimental 138 animal studies (1, 3, 5) . Therefore, inhibition of chemokine activation is important in the control of inflammatory reactions in hypertension-related vascular walls.
The chemokine CCL5 is a strong chemoattractant for memory T cells, monocytes and macrophages, and plays a functional role in the inflammatory responses of many disease progressions, and overproduction of CCL5 occurs during trauma, infection, and inflammation (6~9). However, CCL5 has been shown to down-regulate lipopolysaccharide (LPS)-induced cytokine expression in human peripheral blood monocytes (10) , as well as play a protective role in brains with Alzheimer's disease (11) , and Huntington's disease (12) . Therefore, CCL5 plays diverse roles in accordance with inflammatory and disease states.
Our previous hypertension studies have shown that chemokine CCL5 has down-regulatory effects on expression of angiotensin (Ang) II-induced hypertension mediators, including 12-lipoxygenase (LO) and endothelin (ET)-1, in vascular smooth muscle cells (VSMCs) of spontaneously hypertensive rats (SHR) (13, 14) . In addition, CCL5 has upregulatory effects on AMP-activated protein kinase (AMPK) activity, interleukin-10 (IL-10) levels, and expression of dimethylarginine dimethylaminohydrolase (DDAH)-1, a potent regulator of plasma asymmetric (N G ,N G ) dimethylarginine (ADMA) levels (14, 15) . Therefore, although CCL5 is known as an inflammatory mediator in the pathogenesis of various diseases, it plays an down-regulatory role in Ang II-induced hypertensive mediators expression, which is in contrast to the enhanced roles of proinflammatory chemokines in hypertension development and maintenance (3, 4, 16, 17) .
Although CCL5 has anti-hypertensive effects in SHR VSMCs, the effect of CCL5 on hypertension in vivo has not been reported. In this study, the effects of CCL5 on blood pressure and expressions of hypertension-related mediators were examined in developing hypertension state SHR. 
MATERIALS AND METHODS

Reagents
Animals and experimental protocols
Specific pathogen-free male inbred SHR and normotensive WKY were purchased from Japan SLC Inc. (Shizuoka, Japan). All experimental animals were fed autoclaved food and bedded to minimize exposure to pathogens. SHR and WKY were cared for in accordance with the Guide for the DHSHR received a subcutaneous injection of CCL5 (1.5 μg/kg) twice per day for 3 weeks (18) . Effects of CCL5 on blood pressure and body weight were measured before treatment, weekly during treatment, and 1 day after the final injection. After injecting for 3 weeks, both control and CCL5treated rats were anesthetized by urethane (1.5 g/kg), after which thoracic aorta tissue samples were collected. Effects of CCL5 on expression of hypertension-related mediators were examined in thoracic aorta tissues and VSMCs from thoracic aorta tissues.
Measurement of blood pressure
Blood pressures were measured using the CODA highthroughput tail blood pressure system (Kent Scientific, Torrington, CT, USA). The CODA tail-cuff blood pressure system makes use of volume pressure recording (VPR) sensor system to measure rat tail blood pressure. Several blood pressures were measured for each rat, and the average of four median measurements was used as the mean diastolic and systolic blood pressure.
Immunohistochemistry
To measure thickness of the thoracic aorta wall, transverse sections of 4% paraformaldehyde-fixed, paraffin-embedded thoracic aortas were stained with hematoxylin and eosin (H&E). To assess IL-10, CCL2, CXCL8, AT 1 R, and AT 2 R expression, slides fixed with aortic transverse sections were treated with pepsin for antigen retrieval, and endogenous peroxidase was blocked with 3% H 2 O 2 . After blocking, slides were incubated with rabbit anti-IL-10 antibody (1:50), rabbit anti-CXCL8 antibody (1:50), rabbit anti-CCL2 antibody (1:50), mouse anti-AT 1 R antibody (1:50), and rabbit anti-AT 2 R antibody (1:300) for 1 h at RT, and then treated with EnVision + System-HRP labeled polymer anti-rabbit and anti-mouse antibodies for 1 h at RT. To visualize staining, sections were developed with the DAB substrate chromogen system for 5 min at RT. After staining, thoracic aorta wall thickness (outer diameter (OD)-inner diameter (ID)/2) and wall:lumen ratios (OD-ID)/ID) were calculated.
Preparation of VSMCs
VSMCs were isolated using an explant method from thoracic aorta tissues of DHSHR and WKY as described by Kim et al. (16) . VSMCs were cultured in DMEM supple-mented with 10% FBS and 1% penicillin-streptomycin. All experiments were performed during cell passages 3 to 7.
Prior to stimulation, 95% confluent VSMCs were serumstarved for overnight in DMEM containing 0.1% FBS. 
Preparation of total
Western blotting
After preparing total lysates using PRO-PREP buffer Proteins were visualized using a chemiluminescence detection system (LAS-3000; Fujifilm, Tokyo, Japan).
DDAH activity
Activity of DDAH was measured as described by Ueda et al. (19) . Equal volumes of protein (20 μg) were treated with 4 mmol/l ADMA-0.1 mol/l sodium phosphate buffer (pH 6.5) in a total volume of 0.5 ml for 3 h at 37℃. After stopping the reaction by addition of 4% sulfosalicylic acid, supernatants (100 μl) were boiled with diacetyl monoxime (0.8% wt/vol in 5% acetic acid) and antipyrine (0.5% wt/vol in 50% sulfuric acid). L-citrulline was measured by spectrophotometer at 466 nm (UV-Visible spectrophotometer, Shimadzu UV-160, Kyoto, Japan).
Statistical analysis
All data were expressed as means ± SEM of at least three or four independent experiments. Data were analyzed by one-way analysis of variance (ANOVA) or Kruskal-Wallis test, followed by the Bonferroni or Dunnett's T 3 test.
Statistical significant was set at p value less than 0.05.
RESULTS
CCL5 treatment inhibits elevation of blood pressure in DHSHR
At the beginning of the study, body weight was higher in WKY (293.7±2.98 g) than in DHSHR (253.4±3.09 g). weeks of age, respectively (Fig. 1A) .
After injecting for 3 weeks, we also measured changes in thoracic aorta wall thickness. There was no significant difference in thoracic aorta wall thickness among the three groups. Thoracic aorta wall thickness in SHRi was almost the same as those in both SHRc and WKY. Therefore, injection of CCL5 for 3 weeks had no effect on thoracic aorta wall thickness in DHSHR (Fig. 1B) . SHRi and SHRc thoracic aorta tissues ( Fig. 2A, B) . However, SHRi VSMCs showed slightly elevated AT 2 R protein levels compared to SHRc VSMCs (Fig. 2C, D) .
CCL5 reduces expression of hypertensive mediators and chemokines, and increases IL-10 expression and AMPK activity in DHSHR
Elevated CCL2 and CXCL8 expression patterns are detected in VSMCs and thoracic aorta tissues of SHR (3, 4, 16) . Immunohistochemical staining showed that CCL2 and CXCL8 protein levels were reduced in SHRi, and patterns of mRNA expression in thoracic aorta tissues were similar to protein levels (Fig. 3A, B ). Furthermore, significant reduction of CCL2 and CXCL8 mRNA expression was also observed in SHRi VSMCs (Fig. 3C) . On the other hand, IL-10 mRNA and protein expression levels in thoracic aorta tissues and VSMCs were slightly elevated in SHRi compared to SHRc (Fig. 3) . Expression levels of 12-LO and ET-1 are known to be elevated in VSMCs (20~22).
Consistent with these findings, 12-LO and ET-1 expressions
were elevated in thoracic aorta tissues of SHRc. CCL5 treatment induced the decrease of 12-LO and ET-1 mRNA expression in thoracic aorta tissues (Fig. 4A ). In addition, reduction of 12-LO and ET-1 mRNA and protein levels was observed in SHRi VSMCs (Fig. 4B, C) .
AMPK and DDAH activities are up-regulated by CCL5
and mediate the inhibitory effect of CCL5 on Ang II-induced (14, 15) . In this study, elevated AMPK expression was observed in SHRi thoracic aortas and VSMCs (Fig. 5A ). However, CCL5 treatment had no effect on DDAH-1 expression in thoracic aortas and VSMCs of DHSHR. Additionally, there was no difference in DDAH activity between SHRi and SHRc VSMCs (Fig. 5B) . This study demonstrated the effect of CCL5 on blood pressure and hypertension-related mediators in DHSHR.
12-LO and ET-1 expression in SHR VSMCs
DISCUSSION
Less than 5-week-old SHR are known in a prehypertensive state, 8 to 9 -week-old SHR are in a developing hypertension state, and more than 16-week-old SHR are in an established hypertension state with severe hypertension (23, 24) . Therefore, we observed the effect of CCL5 on blood pressure and hypertension-related mediators in 8-week-old DHSHR.
In general, body weights of both SHR and WKY increase rapidly from 3 weeks to 8~10 weeks and then continue to increase gradually to 30 weeks, and WKY are heavier than SHR (25) . Further, blood pressure of SHR is shown to be 220~250 mmHg after 12 weeks. Whereas the systolic blood pressure of SHR increases with age, that of WKY does not change significantly (25) . In our study using DHSHR, body weight of SHRi also increased gradually to a level greater than that of SHRc by the end of 3 week time of injection.
Blood pressure of SHRc increased with age, whereas that of WKY did not change. However, blood pressure of SHRi was maintained during the treatment period with CCL5.
CCL5 is well known to play a critical role in atherosclerosis and myocardial infarction: in other study, blockage of CCL5 reduced infarct size and post-infarction heart function in mice with chronic cardiac ischemia (26) . Thus, maintenance of blood pressure in SHRi may be attributable to the decrease of cardiac output by CCL5. Unfortunately, we did not measure cardiac output in this study.
Vascular wall thickness affects blood pressure (1). However, aorta wall thickness in DHSHR was unaffected by CCL5 treatment. Long-term treatment of CCL5 is likely to reduce thoracic aorta wall thickness and lead to reduction of blood pressure, unlike DHSHR showing maintenance of blood pressure. Therefore, further studies on long-term or high dose treatment of CCL5 are necessary to clarify the regulatory effects of CCL5 on blood pressure.
To further characterize how CCL5 regulates hypertension, AT 1 R and AT 2 R expression in CCL5-treated thoracic aorta tissues were examined. The rennin-angiotensin system palys a critical function in regulating blood pressure, and Ang II receptors act directly on the pathogenesis of hypertension.
In the present study, CCL5 led to reduced AT 1 R production in DHSHR thoracic aorta tissues and VSMCs. AT 1 R pathway mediates typical Ang II signaling to elicit vascular constriction and VSMCs proliferation (27, 28) . On the other hand, although the functional roles of AT 2 R are still unclear, AT 2 R activation mediates a counter-regulatory effect on AT 1 R (27~29). Inhibition of AT 1 R pathway may up-regulate the activity of AT 2 R promoter (30) . Further, overexpression of AT 2 R downregulates AT 1 R expression in WKY VSMCs (31) . In this study, although CCL5 had little effect on AT 2 R mRNA and protein expression in DHSHR thoracic aorta tissues, AT 2 R mRNA expression was up-regulated slightly in SHRi VSMCs. Expression of AT 2 R are low in adult SHR mesenteric arteries (32) . However, a different result was observed in thoracic aorta tissues of DHSHR. Increased expression level of AT 2 R was detected in SHR compared to WKY.
Blocking of chemokine production is useful for regulating inflammatory reactions in hypertensive vascular walls. CCL2 and CCR2 are known to mediate hypertensive inflammatory changes in the vascular walls of animal models with hypertension (2, 4, 33) . CXCL8 is known to migrate monocytes into the subendothelium during the early stage of atherosclerosis (34) . CXCL8 also directly up-regulates membrane permeability to Ca 2+ , thus inducing vascular contraction during essential hypertension (35) . We previously elucidated the up-regulatory effect of CXCL8 on production of AT 1 R and 12-LO in SHR VSMCs (17) . On the contrary, IL-10 is known to prevent Ang II-induced vasoconstriction by reducing expression of NADPH oxidase (36) as well as regulate vascular function by down-regulating proinflammatory cytokine expression and superoxide production in vascular walls (37, 38) . In addition, IL-10 plays an upregulatory role in the anti-hypertensive activity of CCL5 in SHR VSMCs (39) . In the present study, CCL5 treatment for 3 weeks reduced expression of CXCL8 and CCL2 as well as elevated IL-10 expression in SHR thoracic aorta tissues. These data indicate that CCL5 has regulatory effects on inflammatory reactions in hypertensive arterial walls.
To further elucidate the molecular aspects leading to maintenance of blood pressure in SHRi, the role of CCL5 in modulating 12-LO and ET-1 expression was examined.
The 12-LO pathway of arachidonic acid metabolism is associated with cell growth and pathophysiology of hyper-tension (40~42). The activities of 12-LO and 12(S)hydroxyeicosatetraenoic acid (HETE) are increased in SHR (17, 21) , and their roles in the pathogenesis of Ang IIinduced hypertension have been elucidated (21, 43) . Inhibition of the LO pathway lowers blood pressure in renovascular hypertension (44) . Here, CCL5 treatment was shown to reduce 12-LO expression in thoracic aorta tissues and VSMCs from DHSHR. In addition, CCL5 treatment reduced ET-1 expression in thoracic aorta tissues and VSMCs of DHSHR. Endothelins (ET-1, ET-2 and ET-3) increase vascular tone and blood pressure (45) . ET-1 is the most abundant ET produced by vascular cells (46) . ET-1 induces vasoconstriction and elicits vascular remodeling in vascular walls (47) . AT 1 R pathway mediates the expression of 12-LO and ET-1 (17, 48) . Thus, down-regulation of 12-LO and ET-1 expression by CCL5 appears to be related to AT 1 R inhibition by CCL5.
Although AMPK is known for its roles in energy homeostasis, there have been various studies on the relationship between AMPK and regulation of blood pressure (49~51).
AMPK activators, such as metformin and AICAR, have been reported to reduce blood pressure in experimental animals and humans, and AMPK activation exhibits improvement of endothelial function and inhibition of VSMC proliferation (52, 53) .
Blocking of DDAH activity has been shown to prevent nitric oxide (NO)-mediated vascular relaxation (54~56).
ADMA is a major risk factor for cardiovascular diseases and NO bioavailability, and regulated by DDAH (54, 55) .
DDAH are expressed as two isoforms, DDAH-1 and DDAH -2. Plasma ADMA is regulated by DDAH-1, whereas maintenance of endothelial function in vascular resistance is regulated by DDAH-2 (54, 57) . CCL5 directly increases DDAH-1expression but not DDAH-2 in SHR VSMCs, and basal expression level of DDAH-2 in thoracic aorta tissues and VSMCs of SHR is similar to those of WKY (14, unpublished data). CCL5 increases DDAH-1 expression and AMPK phosphorylation as well as attenuates the inhibitory effect of Ang II on AMPK and DDAH activities in SHR VSMCs (14, 15) . In this study, CCL5 treatment for 3 weeks also elevated AMPK activity, although it had no effect on DDAH activity and DDAH-1 expression in DHSHR thoracic aortas and VSMCs. CCL5 significantly increases AT 2 R expression in SHR VSMCs in vitro (13) , and expression of DDAH-1 and reduction of Ang II-induced DDAH-1 inhibition by CCL5 are mediated via AT 2 R in SHR VSMCs (14) . Interestingly, although we detected a slight increase in AT 2 R production in SHRi VSMCs, overall up-regulation of AT 2 R in SHRi thoracic aorta tissues was not detected.
This lack of response of DDAH activity to CCL5 treatment may be related to AT 2 R expression in SHRi thoracic aorta tissues. We expect that long-term or high dose treatment of 
